Defibrillators Industry

The global defibrillators market size was estimated at USD 7.32 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 8.1% from 2024 to 2030. Increasing product development activities, rising incidence of sudden cardiac arrest, growing awareness among the general public, and supportive initiatives by governments & healthcare organizations are some of the key factors fueling industry growth. In May 2021, Rapid Response Revival Research Ltd.-an Australian company-received a CE mark for its CellAED, the world’s first personal automated external defibrillator (AED) for home use. This supported the company’s growth strategy.

Increasing geriatric population globally and technological advancements are other key factors that are projected to significantly impact market growth. The older population, particularly those aged between 65 years and above, is more vulnerable to chronic diseases, such as cardiovascular diseases (CVDs), which often require the placement of defibrillators to restore a normal heart rhythm by delivering an electric shock to the heart. For instance, in November 2022, the article "Senior Population Statistics: A Portrait of Aging Americans" reported that around 54.1 million (16.3%) individuals in the U.S. are aged 65 years or above. Thus, the growing geriatric population contributes to the increasing product demand.

Gather more insights about the market drivers, restrains and growth of the Global Defibrillators market

Defibrillators Market Segments Highlights:

  • Product Insights

Implantable cardioverter defibrillators (ICDs) dominated the market with a share of over 52.03% in 2023. Key factors driving this segment growth include rising adoption of these devices due to the high prevalence of CVDs, high geriatric population in key markets, and growing product improvements by major companies. For instance, in December 2021, Boston Scientific initiated the MODULAR ATP clinical trial to assess the safety, performance, and efficacy of the mCRM Modular Therapy System. Comprising two cardiac rhythm management devices, namely the EMBLEM MRI subcutaneous implantable defibrillator (S-ICD) system and another component, the mCRM system's trial aims to evaluate its functionalities comprehensively.

  • End-use Insights

Hospitals segment held the largest revenue share of over 79.14% in 2023 owing to the higher volume of cardiac cases in hospitals and surgeries performed in hospital settings. Both ICDs and external defibrillators are widely used in hospitals to deliver treatment to patients of sudden cardiac arrest and for other indications. For instance, as of January 2021, Boston Scientific reported the global distribution of approximately 659,000 ICDs. This figure represented a noteworthy surge of 59,000 units compared to the 600,000 ICDs distributed by January 2020, underscoring a substantial increase in demand.

  • Regional Insights

North America held the largest revenue share of more than 42.1% in 2023 owing to several factors, including an increasing prevalence of heart diseases, a growing elderly population, strong presence of industry players in the region, and well-developed healthcare infrastructure. It heightened awareness among the public and healthcare stakeholders regarding available technologies. For instance, according to the CDC, in 2021, approximately 695,000 individuals in the U.S. died from heart disease (1 in every 5 deaths). From 2018 to 2019, the U.S. spent around USD 239.9 billion. In addition, rising number of heart-related disorders and technological advancements are driving the regional market growth.

Browse through Grand View Research's Medical Devices Industry Research Reports.

Key Companies & Market Share Insights

The market has been characterized by intense competition. Market players incorporate various strategic initiatives to increase their market share. These include product development, regional expansion, partnerships and collaborations, and mergers & acquisitions. For instance, In August 2022, Medtronic reported the achievement of trial endpoints for its investigational EV ICD (extravascular implantable cardioverter defibrillator) system. This innovative device is designed to mitigate specific risks associated with traditional transvenous ICDs by sitting its lead outside the heart and veins, positioned beneath the sternum, through a minimally invasive approach.

Key Defibrillators Companies:

  • Medtronic
  • Abbott
  • Boston Scientific Corporation
  • BIOTRONIK SE & Co. KG
  • MicroPort Scientific Corporation
  • Koninklijke Philips N.V.
  • Stryker
  • ZOLL Medical Corporation (Asahi Kasei)
  • Nihon Kohden Corporation
  • Schiller AG

Segments Covered in the Report

Grand View Research has segmented the global defibrillators market on the basis of product, end-use, and region:

Defibrillators Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Implantable Cardioverter Defibrillators (ICD)
    • S-ICD
    • T-ICD
  • External Defibrillators (ED)
    • Manual ED
    • Automated ED
    • Wearable Cardioverter Defibrillators

Defibrillators End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital
  • Pre-hospital
  • Public Access Market
  • Alternate Care Market
  • Home Healthcare

Defibrillators Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Order a free sample PDF of the Defibrillators Market Intelligence Study, published by Grand View Research.